Empagliflozin Powder is a structurally unique selective sodium-glucose cotransporter 2 (SGLT2) inhibitor. Structurally, it uses a C-glycosidic bond to connect the aromatic ring and the glycosyl group, a key difference from traditional O-glycosides. This C-glycosidic bond provides extremely high enzymatic stability, significantly improving the drug's tolerance to acidic environments and to enzymatic degradation, resulting in strong metabolic stability and a long half-life in the gastrointestinal tract and bloodstream. Its core is a substituted benzene ring, with chlorine atoms and ethoxybenzyl substituents on the aromatic ring side chains, giving the molecule moderate hydrophobicity and making it easier to penetrate cell membranes and bind to target proteins.
Furthermore, the tetrahydropyranose ring of Empagliflozin has multiple chiral centers and hydroxyl groups, making its binding to the SGLT2 transporter more directional and selective. It is stable in its crystalline form, has moderate solubility, and is usually available as an oral tablet with excellent oral absorption. Through precise design of its stereochemical characteristics and substituent distribution, researchers have effectively improved its bioavailability and selective inhibitory ability while maintaining a balance between lipophilicity and hydrophilicity, making Empagliflozin one of the most structurally mature and selective representative compounds in the current field of SGLT2 inhibitors.
Shaanxi Medibridge Biotech Co., Ltd. focuses on the supply of pharmaceutical raw materials and research-use compounds. We support customers with stable quality, clear specification communication, flexible packaging options, and document-related support for different project stages.
COA
|
|
||
|
Product Name |
CAS Number |
Batch Number |
|
Empagliflozin Powder |
864070-44-0 |
MB2606130045 |
|
Manufacturer Date |
Analysis Date |
Expiry Date |
|
2026/6/13 |
2026/6/15 |
2028/6/15 |
|
Sample Qty Base |
Packing |
Test Method |
|
100KGS |
25KG/drum |
HPLC |
|
|
||
|
Item |
Standard |
Results |
|
Appearance |
White Powder |
Conform |
|
Odor |
Characteristic |
Conform |
|
Assay |
≥98.0% |
98.52% |
|
Particle Size |
100% pass 80mesh |
Conform |
|
Moisture |
<5.0% |
Conform |
|
Ash Content |
<4.0% |
Conform |
|
Solvent Residue |
Eur.Pharm |
Conform |
|
Total Heavy Metals |
<10 ppm |
Conform |
|
Arsenic |
<1.0 ppm |
Conform |
|
Lead |
<1.0 ppm |
Conform |
|
Mercury |
<0.5 ppm |
Conform |
|
DDT |
<0.2ppm |
Conform |
|
E. Coli |
Negative |
Negative |
|
GMO Status |
Complies |
GMO Free |
|
Irradiation |
Complies |
Irradiation Free |
|
Conclusion |
The batch conforms to the IN-HOUSE standard |
|
|
|
||
Primary Molecular Mechanism
Renal SGLT2 Inhibition
SGLT2 reabsorbs much of the filtered glucose in the kidney's proximal tubule. Empagliflozin inhibits this transporter, lowering the renal threshold for glucose and increasing urinary glucose excretion. It also reduces sodium reabsorption, increasing sodium delivery farther along the nephron. These linked effects provide starting points for studies of glucose handling, osmotic diuresis, tubuloglomerular feedback, and intraglomerular pressure. accessdata.fda.gov
A transporter assay should distinguish direct SGLT2 inhibition from downstream changes caused by altered glucose or sodium availability. Useful controls include transporter-expressing and control cells, concentration-dependent uptake measurements, viability testing, and confirmation of the compound's dissolved concentration.

Renal and Metabolic Physiology

Empagliflozin offers a way to examine how changing kidney glucose reabsorption affects broader physiology. Research endpoints may include urinary glucose, urine volume, sodium handling, body-fluid balance, and kidney function over time. The glucose-lowering response depends in part on filtered glucose delivery: the product label notes that urinary glucose excretion declines as kidney function decreases, even though systemic empagliflozin exposure can increase.
This distinction matters when interpreting an experiment. A plasma drug concentration, a glucose-transport assay, and a whole-kidney physiological response answer different questions and should not be used interchangeably.
Cardiovascular and Kidney Outcome Research
Empagliflozin has been studied in large clinical outcome programs across type 2 diabetes with established cardiovascular disease, heart failure, and chronic kidney disease. U.S. labeling includes indications related to cardiovascular and kidney outcomes for specified populations. Those clinical results establish effects of the tested drug products and study regimens; they do not establish that an unformulated powder will produce the same exposure or outcome.
For mechanistic research, an important open question is how much of a measured cardiac or kidney response follows from renal glucose and sodium transport, and how much involves subsequent changes in circulating volume, hemodynamics, or tissue signaling. A proposed secondary mechanism should be tested directly rather than inferred from an outcome alone.

Metabolism and Transporter Interactions

Human metabolism involves glucuronidation, with UGT2B7, UGT1A3, UGT1A8, and UGT1A9 implicated in vitro. The label identifies three glucuronide conjugates and reports no major metabolite in plasma. It also describes empagliflozin as a substrate of P-glycoprotein and BCRP, while indicating that inhibition of major CYP450 enzymes is not expected at clinically relevant exposure. accessdata.fda.gov
This profile makes empagliflozin relevant to UGT metabolism, transporter, and drug-interaction studies. In vitro transporter results should nevertheless be interpreted alongside measured free concentrations and appropriate positive controls; substrate status alone does not establish a clinically important interaction.
Metabolism and Transporter Interactions
Human metabolism involves glucuronidation, with UGT2B7, UGT1A3, UGT1A8, and UGT1A9 implicated in vitro. The label identifies three glucuronide conjugates and reports no major metabolite in plasma. It also describes empagliflozin as a substrate of P-glycoprotein and BCRP, while indicating that inhibition of major CYP450 enzymes is not expected at clinically relevant exposure.
This profile makes empagliflozin relevant to UGT metabolism, transporter, and drug-interaction studies. In vitro transporter results should nevertheless be interpreted alongside measured free concentrations and appropriate positive controls; substrate status alone does not establish a clinically important interaction.

Solubility, Dissolution, and Oral Formulation

Very slight water solubility makes sample preparation and dissolution important for both cell work and dosage-form development. A clear concentrated stock can precipitate after dilution into culture medium, so the nominal amount added may differ from the amount available to cells. Formulation studies should assess particle-size distribution, solid form, dissolution in appropriate media, blend and content uniformity, and stability in the intended package.
Changes that improve dissolution should be evaluated against measured exposure, rather than assumed to improve performance. A carrier or processing method may change release, absorption, or stability in ways that must be tested for the specific product.
FAQ
What is the primary biological target and mechanism of action for Empagliflozin?
Empagliflozin is a highly selective inhibitor of sodium-glucose cotransporter 2 (SGLT2) that blocks renal glucose reabsorption in the proximal renal tubules.
What are the main biological research applications for Empagliflozin Powder?
It is widely investigated in metabolic disease models, diabetic nephropathy, heart failure, cardiovascular protection, and cellular bioenergetics research.
How should Empagliflozin Powder be dissolved for cell-based in vitro assays?
It should be dissolved in high-grade DMSO to prepare a concentrated stock solution before serial dilution into aqueous culture media.
What are the recommended long-term storage conditions for Empagliflozin Powder?
The powder should be kept sealed at -20C in a dry, light-protected environment to ensure chemical stability.
Hot Tags: empagliflozin powder, China empagliflozin powder manufacturers, suppliers, factory, Cilostazol Powder, dicyclanil veterinary drug substance, heparin sodium laboratory grade powder, mirabegron therapeutic compound, progesterone active molecule powder, progesterone active pharmaceutical ingredient



